二甲双胍降低听力损失风险:一项回顾性队列研究
基于台湾全民健康保险数据库的回顾性队列研究,纳入1999至2005年新发糖尿病的292,071例二甲双胍曾用者和18,200例从未使用者,随访至2011年底。曾用者听力损失风险低于从未使用者(HR 0.534,95%CI 0.501-0.569),且随累积用药时长和剂量增加呈剂量-反应模式降低。
要点
- 二甲双胍曾用者较从未使用者听力损失风险降低(HR 0.534,95%CI 0.501-0.569)。
- 累积用药时长和剂量增加,听力损失风险降低幅度更大,呈剂量-反应模式。
- 倾向评分匹配队列结论未实质改变,混合性听力损失风险降低在匹配队列中未达统计学显著。
核心结论
- 使用二甲双胍的患者听力损失风险以剂量-反应模式降低。
研究设计与样本
- 回顾性队列研究,数据来自台湾全民健康保险数据库。
- 纳入1999至2005年新发糖尿病的292,071例二甲双胍曾用者和18,200例从未使用者,随访听力损失至2006年1月1日至2011年12月31日。
- 采用倾向评分加权估计风险比(HR)。
主要发现
- 听力损失新诊断:曾用者10,085例,从未使用者1,072例;发病率分别为每10万人年738.09和1,366.83。
- 曾用者与从未使用者比较的HR为0.534(95%CI 0.501-0.569)。
- 累积用药时长三分位(<27.07个月、27.07-59.13个月、>59.13个月)的HR分别为0.912(95%CI 0.852-0.975)、0.544(95%CI 0.508-0.582)、0.275(95%CI 0.255-0.295)。
- 累积剂量三分位(<796.70 g、796.70-2020.15 g、>2020.15 g)的HR分别为0.900(95%CI 0.841-0.962)、0.531(95%CI 0.496-0.569)、0.293(95%CI 0.273-0.315)。
- 亚型分析提示感音神经性听力损失的风险降低较传导性更显著;倾向评分匹配队列中混合性听力损失的风险降低未达统计学显著,而未匹配队列中显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the risk of hearing loss with regard to metformin exposure. STUDY DESIGN: Retrospective cohort. SETTING: Taiwan's National Health Insurance database. METHODS: We enrolled 292,071 ever users and 18,200 never users of metformin with new-onset diabetes mellitus from 1999 to 2005 and followed them for hearing loss from January 1, 2006, to December 31, 2011. Hazard ratios (HRs) weighted by propensity score were estimated. RESULTS: Hearing loss was newly diagnosed in 10,085 ever users and 1072 never users. Their respective incidence rates (per 100,000 person-years) were 738.09 and 1366.83. The HR comparing ever-to-never users was 0.534 (95% confidence interval [CI]: 0.501-0.569]. The HR (95% CI) for the first (<27.07 months), second (27.07-59.13 months), and third (>59.13 months) tertiles of cumulative duration of metformin therapy were 0.912 (0.852-0.975), 0.544 (0.508-0.582), and 0.275 (0.255-0.295), respectively; and were 0.900 (0.841-0.962), 0.531 (0.496-0.569), and 0.293 (0.273-0.315), respectively, for the first (<796.70 g), second (796.70-2020.15 g), and third (>2020.15 g) tertiles of cumulative dose. The magnitude of risk reduction became more remarkable in corresponding to the increasing tertiles of the defined daily dose prescribed. Subtype analyses suggested that the risk reduction was more significant for sensorineural than conductive hearing loss. Findings derived from a propensity score-matched cohort did not substantially change the conclusions, and the risk reduction for mixed hearing loss was not statistically significant in the matched cohort as significantly observed in the unmatched cohort. CONCLUSION: The risk of hearing loss is reduced in a dose-response pattern in patients who use metformin.
引用
- Tseng CH. Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study. Otolaryngol Head Neck Surg. 2023. PMID: 36939574. doi:10.1002/ohn.232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。